openPR Logo
Press release

SMi’s Exclusive Interview with MedImmune Principal Scientist just released

07-25-2018 05:06 PM CET | Health & Medicine

Press release from: SMi Group

SMi’s Exclusive Interview with MedImmune Principal

An exclusive interview with Dr. Antonio DiGiandomenico, Principal Scientist, MedImmune has been released
SMi Reports: An exclusive interview with Dr. Antonio DiGiandomenico, Principal Scientist at MedImmune on challenges and his vision for the future of AMR R&D has been released in the run-up to the 3rd annual Superbugs & Superdrugs USA Conference taking place in Iselin, New Jersey on November 12 - 13, 2018.
SMi Group is proud to present some insightful content to you, who will be speaking at the 3rd annual Superbugs & Superdrugs USA Conference, a leading scientist in AMR R&D: Dr. Antonio DiGiandomenico, Principal Scientist, MedImmune. SMi caught up with Dr. DiGiandomenico to talk about his role in the field, his vision on challenges and the future for the development of novel anti-infectives.
Dr. Antonio DiGiandomenico is currently a Principal Scientist in the Department of Microbial Sciences at MedImmune/AstraZeneca and has 20 years of experience in microbiology and immunology.
--SNAPSHOT OF INTERVIEW--
Q. What do you see as the greatest hurdle to developing novel and effective anti-infectives?
A. Cost to develop novel drugs is a major drawback to large pharma due to the lack of incentives, which factors from: 1) an overall public perception that antibiotics need to be cheap. 2) the rate of antibiotic resistance development can be so fast that there could be widespread resistance shortly after a new antibiotic reaches the market. 3) broad-spectrum antibiotic usage is detrimental to the host and should only be used in special circumstances.
Q. What do you think could be and should be done to address this?
A. To start, regulatory agencies need to develop a path for the development of narrow-spectrum drugs. In addition, there should be greater incentives for the development of novel anti-infectives. The US is behind their EU counterparts in implementing similar to Innovative Medicines Initiative programs, but there is current movement in the positive direction with the recent introduction of the Antibiotic Resistance Leadership Group (ARLG).
Q. What would you say is the biggest barrier to implementation of novel anti-infectives in common treatment plans and the commercial market?
A. I firmly believe that the novel anti-infectives of the future will be those that target a limited number or single pathogens.
- Download the full interview online -
Join Dr. Antonio DiGiandomenico this November as he will be presenting: ‘Immunotherapeutics Targeting Pseudomonas Aeruginosa Acute and Persistent Infections’. The presentation will introduce novel anti-Pseudomonal mAbs and their mechanisms of action. Activity will also be discussed in multiple animal models when used in both prophylaxis and treatment indications. Dr. DiGiandomenico will also address synergy with antibiotic treatment and activity against biofilms.
Further details and speaker interview available online
Bookings made by 31st August will be eligible for the special summer discount and save US$200, by using the voucher code: P266EM

SMi presents the 3rd annual industry leading conference:
Superbugs & Superdrugs USA
Date: 12th – 13th November 2018
Location: Renaissance Woodbridge Hotel, Iselin, New Jersey
Website: www.superbugs-usa.com/pr6

---end---
Contact Information:
For sponsorship bookings, contact Alia Malick Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
Book your place online at www.superbugs-usa.com/pr6
Follow us on: Twitter - @SMIpharm & #smibugs | LinkedIn - @SMi Pharma

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

SMi Group Ltd
1 Westminster Bridge Rd, South Bank, London SE1 7XW
+44 020 7827 6000

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SMi’s Exclusive Interview with MedImmune Principal Scientist just released here

News-ID: 1145114 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for DiGiandomenico

Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018. Antimicrobial resistance, leading to the